MYGN (Myriad Genetics Corp) Pangali Forward P/E

Myriad Genetics, Inc. (MYGN) is strengthening its stability by expanding its testing spectrum from oncology to psychiatry to minimize insurance risks. The company's forward P/E ratio confirms this trend, with the value holding at 0.00. Efficiency is driven by the rapid delivery of biomaterials to laboratories, while system reliability is supported by external cloud data storage with full control over the scientific core.

Rasio rega marang bathi mangsa ngarep: myriad.com (MYGN) kanggo 04.07.2022 - 15.11.2026

Rincian analitis perusahaan Myriad Genetics (MYGN)

- rega saiki lan proyeksi nilai saham:

Kutipan saham Myriad Genetics Corp|MYGN - Konsensus nilai wajar

- indikator valuasi pasar bisnis:

Kapitalisasi pasar Myriad Genetics Corp|MYGN - Nilai Perusahaan

- informasi kapitalisasi buku:

Aset Bersih saben Siji Saham Myriad Genetics|MYGN - Kapitalisasi Akuntansi|Rasio Kapitalisasi Pasar marang Nilai Buku myriad.com|MYGN - Total Aset Perusahaan

- data liabilitas lan likuiditas perusahaan:

Utang marang Ekuitas Myriad Genetics, Inc.|MYGN - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang ekuitas Myriad|MYGN - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku Myriad Genetics, Inc.|MYGN - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan Myriad Genetics|Likuiditas cepet myriad.com

- indikator profitabilitas perusahaan lan kelipatan valuasi:

MYGN - Asil keuangan resik|Bathi sing dikarepake Myriad Genetics, Inc.|MYGN - Koefisien rega marang bathi|Prakiraan rega marang bathi Myriad Genetics Inc|MYGN - Rega marang bathi kanthi panyesuaian wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Myriad Genetics|MYGN - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Myriad Genetics|MYGN - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi EPS kuartalan myriad.com|MYGN - Wutah bathi ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Myriad Genetics, Inc.

- indikator pendapatan dodolan lan penghasilan bisnis:

MYGN - Volume dodolan perusahaan|Volume dodolan mangsa ngarep perusahaan Myriad Genetics Corp|MYGN - Rasio kapitalisasi pasar marang pendapatan|Multiplikator Forward P/S Myriad

Analisis kabeh metrik perusahaan:MYGN Myriad

The forward P/E reflects the market value of the business relative to its expected annual earnings. For Myriad Genetics, Inc. (MYGN), this calculation links market capitalization to the monetization of its leadership in high-precision genetics. By analyzing the company's projected price-to-earnings multiple on GURU.Markets, an investor can identify valuation deviations from the fundamental trend. Low values may indicate an undervaluation of a brand that enjoys the trust of oncologists, allowing for the differentiation of sustainable growth from temporary market fluctuations.

Pesaing utama

Pangali Forward P/E CAI|Guardant360 - Rasio rega marang bathi mangsa ngarep|Pangali Forward P/E VCYT (Veracyte Diagnostics)|Pangali Forward P/E celcuity.com CELC|GRAL - Rega marang bathi mangsa ngarep|CSTL (Castle Biosciences, Inc.) - Rasio rega marang bathi mangsa ngarep|Burning Rock Biotech Ltd. (BNR) - Rega marang bathi mangsa ngarep|VolitionRx Ltd (VNRX) - Pangali Forward P/E|Rega marang bathi mangsa ngarep Biodesix, Inc.|Rega marang bathi mangsa ngarep PRPO|Prakiraan rega marang bathi CHEK (Check-Cap Ltd.)|MYNZ - Rasio prakiraan rega marang bathi|Pangali Forward P/E OCX (OncoCyte Inc)